XORTX Therapeutics Inc. (XRTX)
NASDAQ: XRTX · Real-Time Price · USD
0.8400
+0.0399 (4.99%)
At close: Aug 22, 2025, 4:00 PM
0.8200
-0.0200 (-2.38%)
After-hours: Aug 22, 2025, 6:23 PM EDT

XORTX Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Jan '22 Dec '20 2016 - 2020
Selling, General & Admin
1.892.192.281.931.220.4
Upgrade
Research & Development
0.510.182.426.760.680.22
Upgrade
Operating Expenses
2.542.624.969.242.310.87
Upgrade
Operating Income
-2.54-2.62-4.96-9.24-2.31-0.87
Upgrade
Interest Expense
-----0-0.01
Upgrade
Interest & Investment Income
0.090.120.250.1--
Upgrade
Currency Exchange Gain (Loss)
-0.03-0.07-0.01-0-0.010
Upgrade
Other Non Operating Income (Expenses)
0.61-0.752.551.420.75-0.16
Upgrade
EBT Excluding Unusual Items
-1.88-3.31-2.16-7.72-1.58-1.03
Upgrade
Asset Writedown
------0.05
Upgrade
Other Unusual Items
-----0.07
Upgrade
Pretax Income
-1.88-3.31-2.16-7.72-1.58-1.01
Upgrade
Net Income
-1.88-3.31-2.16-7.72-1.58-1.01
Upgrade
Net Income to Common
-1.88-3.31-2.16-7.72-1.58-1.01
Upgrade
Shares Outstanding (Basic)
332111
Upgrade
Shares Outstanding (Diluted)
332111
Upgrade
Shares Change (YoY)
46.89%45.25%33.91%35.25%47.77%24.34%
Upgrade
EPS (Basic)
-0.55-1.15-1.09-5.22-1.44-1.36
Upgrade
EPS (Diluted)
-0.55-1.15-1.09-5.22-1.44-1.36
Upgrade
Free Cash Flow
-3.08-3.68-6.59-8.19-4.8-0.57
Upgrade
Free Cash Flow Per Share
-0.90-1.28-3.32-5.53-4.39-0.77
Upgrade
EBITDA
-2.55-2.58-4.88-9.22-2.3-0.85
Upgrade
D&A For EBITDA
-0.010.040.070.020.010.02
Upgrade
EBIT
-2.54-2.62-4.96-9.24-2.31-0.87
Upgrade
Updated Nov 15, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q